• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Personalized Depression Treatment

Traditional treatment and medications don't work for a majority of people who are depressed. Personalized treatment may be the answer.

Cue is an intervention platform for digital devices that converts passively collected smartphone sensor data into personalized micro-interventions to improve mental health. We looked at the best-fitting personal ML models for each individual, using Shapley values to determine their feature predictors. This revealed distinct features that changed mood in a predictable manner over time.

Predictors of Mood

Depression is a leading cause of mental illness around the world.1 Yet the majority of people suffering from the condition receive treatment. To improve the outcomes, doctors must be able to identify and treat patients who are most likely to benefit from certain treatments.

The treatment of depression can be personalized to help. Using mobile phone sensors as well as an artificial intelligence voice assistant, and other digital tools researchers at the University of Illinois Chicago (UIC) are developing new methods to determine which patients will benefit from which treatments. Two grants worth more than $10 million will be used to discover biological and behavioral predictors of response.

So far, the majority of research on predictors for depression treatment effectiveness has focused on the sociodemographic and clinical aspects. These include demographics like gender, age, and education, as well as clinical aspects such as symptom severity, comorbidities and biological markers.

Very few studies have used longitudinal data in order to predict mood of individuals. Many studies do not take into consideration the fact that moods vary significantly between individuals. Therefore, it is critical to develop methods that permit the identification of different mood predictors for each person and treatments effects.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. The team can then develop algorithms to recognize patterns of behavior and emotions that are unique to each person.

The team also devised a machine-learning algorithm that can create dynamic predictors for each person's mood for depression. The algorithm combines these individual variations into a distinct "digital phenotype" for each participant.

The digital phenotype was associated with CAT DI scores, a psychometrically validated symptom severity scale. The correlation was weak however (Pearson r = 0,08; P-value adjusted by BH 3.55 10 03) and varied greatly among individuals.

Predictors of Symptoms

Depression is among the world's leading causes of disability1 but is often not properly diagnosed and treated. Depression disorders are usually not treated due to the stigma attached to them and the absence of effective treatments.

To assist in individualized treatment, it is crucial to identify predictors of symptoms. However, the methods used to predict symptoms rely on clinical interview, which is not reliable and only detects a limited variety of characteristics that are associated with situational depression treatment.2

Machine learning can be used to blend continuous digital behavioral phenotypes that are captured by smartphone sensors and a validated online mental health tracker (the Computerized Adaptive Testing Depression Inventory, the CAT-DI) with other predictors of severity of symptoms could increase the accuracy of diagnostics and treatment efficacy for depression. Digital phenotypes are able to are able to capture a variety of unique behaviors and activities that are difficult to capture through interviews, and allow for high-resolution, continuous measurements.

The study included University of California Los Angeles students with moderate to severe depression symptoms who were taking part in the Screening and Treatment for Anxiety and Depression program29 that was developed as part of the UCLA Depression Grand Challenge. Participants were sent online for support or to clinical treatment according to the degree of their depression. Patients who scored high on the CAT-DI of 35 or 65 were allocated online support via the help of a peer coach. those with a score of 75 patients were referred for psychotherapy in person.

At the beginning, participants answered an array of questions regarding their personal demographics and psychosocial features. The questions covered age, sex, and education, marital status, financial status and whether they were divorced or not, the frequency of suicidal thoughts, intentions or attempts, as well as the frequency with which they consumed alcohol. The CAT-DI was used for assessing the severity of depression symptoms on a scale from 100 to. The CAT-DI tests were conducted every other week for participants that received online support, and weekly for those receiving in-person care.

Predictors of Treatment Reaction

Research is focused on individualized treatment for depression. Many studies are aimed at finding predictors that can aid clinicians in identifying the most effective medications to treat each patient. Particularly, pharmacogenetics can identify genetic variants that influence how the body's metabolism reacts to antidepressants. This lets doctors select the medication that are likely to be the most effective for every patient, minimizing the amount of time and effort required for trial-and-error treatments and avoiding any side negative effects.

Another promising approach is building models of prediction using a variety of data sources, including data from clinical studies and neural imaging data. These models can be used to identify which variables are most predictive of a specific outcome, like whether a medication can improve symptoms or mood. These models can also be used to predict a patient's response to an existing treatment which allows doctors to maximize the effectiveness of their treatment currently being administered.

A new generation uses machine learning methods such as supervised and classification algorithms such as regularized logistic regression, and tree-based methods to integrate the effects of multiple variables to improve the accuracy of predictive. These models have been proven to be useful for forecasting treatment outcomes, such as the response to antidepressants. These techniques are becoming increasingly popular in psychiatry and will likely become the norm in the future clinical practice.

Research into the underlying causes of depression continues, as do predictive models based on ML. Recent findings suggest that depression is related to dysfunctions in specific neural networks. This suggests that an individualized treatment for depression will be based on targeted therapies that restore normal function to these circuits.

One method of doing this is by using internet-based programs that can provide a more individualized and personalized experience for patients. A study showed that an internet-based program improved symptoms and provided a better quality of life for MDD patients. Furthermore, a randomized controlled study of a customized treatment for depression demonstrated sustained improvement and reduced adverse effects in a large percentage of participants.

Predictors of adverse effects

In the treatment of depression, one of the most difficult aspects is predicting and determining the antidepressant that will cause very little or no adverse effects. Many patients take a trial-and-error approach, with several medications prescribed before finding one that is effective and tolerable. Pharmacogenetics offers a fresh and exciting way to select antidepressant medications that is more efficient and targeted.

There are many predictors that can be used to determine which antidepressant should be prescribed, including genetic variations, phenotypes of patients such as ethnicity or gender and the presence of comorbidities. However, identifying the most reliable and accurate factors that can predict the effectiveness of a particular treatment will probably require randomized controlled trials of much larger samples than those typically enrolled in clinical trials. This is because it may be more difficult to detect interactions or moderators in trials that comprise only one episode per participant instead of multiple episodes spread over a period of time.

Additionally, the prediction of a patient's response to a specific medication will also likely need to incorporate information regarding symptoms and comorbidities in addition to the patient's personal experience of its tolerability and effectiveness. At present, only a handful of easily measurable sociodemographic variables as well as clinical variables are reliable in predicting the response to MDD. These include gender, age, race/ethnicity, BMI, SES and the presence of alexithymia.

Many issues remain to be resolved in the use of pharmacogenetics in the treatment of depression. First, it is essential to have a clear understanding and definition of the genetic factors that cause depression, as well as an accurate definition of a reliable indicator of the response to treatment. In addition, ethical issues, such as privacy and the appropriate use of personal genetic information should be considered with care. In the long-term pharmacogenetics can be a way to lessen the stigma that surrounds mental health treatment and improve the treatment outcomes for patients with depression treatment free. As with any psychiatric approach, it what is the best treatment for anxiety and depression important to carefully consider and implement the plan. In the moment, it's ideal to offer patients a variety of medications ect for treatment resistant Depression (Chessdatabase.science) depression that are effective and encourage them to speak openly with their doctor.